Windtree Therapeutics, a Nasdaq-listed biotech firm, announced plans to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, following its recent all-time high price of $808. To fund this acquisition, the company is raising $520 million, augmenting its earlier commitment of $200 million to BNB purchases. They will partner with Kraken for asset custody. This is part of a growing trend among public companies investing in cryptocurrencies. Windtree aims to bolster its balance sheet and strategies with these digital assets. CEO Jed Latkin emphasized the importance of stockholder approval for this initiative. Despite a recent decline in its stock price, the company's shares have surged 162% over the past month due to these developments. Other companies, like Chinese blockchain firm Nano Labs, are demonstrating similar interest in BNB by planning substantial investments as well.

Source šŸ”—